Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin for complex drug-susceptible tuberculosis
NCT04768231Phase 2Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of rifampicin in Tuberculosis (TB), sponsored by Vall d'Hebron Research Institute. Status: unknown.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04768231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768231.